Skip to main content
Premium Trial:

Request an Annual Quote

Signature Dx to Manage CRC Clinical Trials in Germany for OncoMethylome

NEW YORK (GenomeWeb News) – OncoMethylome Sciences said Tuesday it has contracted the German company Signature Diagnostics to help it manage the German component of its multi-center clinical trials for a colorectal cancer diagnostic.
 
Under the agreement, OncoMethylome also has acquired a minority interest in Potsdam-based Signature Diagnostics, and it will give the company an up-front payment as well as service fees. Additional financial terms of the agreement were not disclosed.
 
The deal also gives OncoMethylome first negotiation rights on a test Signature Diagnostics is developing to predict colorectal cancer patient outcomes.
 
"Signature Diagnostics demonstrated that it is able to support a large, multi-center, prospective clinical trial in colorectal cancer with its trial technology,” OncoMethylome CEO Herman Spolders said in a statement.
 
Liege, Belgium-based OncoMethylome is focused on developing tests for detecting cancer in its early stages, predicting patient response to therapeutics, and predicting the chance of cancer recurrence.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.